MENU
X
Close Menu CLOSE
company-header-background

GenVoy-ILM™

Non-Viral LNP Delivery of RNA

Overview
GenVoy-ILM™ is an ionizable lipid mix that enables the rapid and easy production of RNA-loaded lipid nanoparticles (LNPs) using the NanoAssemblr™ platform.  GenVoy-ILM is the simplest way to get started with LNPs - the most advanced non-viral technology for delivering nucleic acids.

An exclusive ionizable cationic lipid is the key to:

  • • Excellent encapsulation
  • • Low toxicity
  • • High gene delivery potency

 

Start developing applications such as

  • • RNAi medicines
  • • Gene editing
  • • Protein/Enzyme replacement
  • • RNA vaccines

LNPs mimic low-density lipoproteins and are taken up through an endogenous pathway where they are designed to trigger the release of nucleic acids in the cytoplasm.

Endogenous Uptake

Lipid Nanoparticles

LNPs contain a pH-sensitive ionizable cationic lipid that attract anionic nucleic acids to form the core of self-assembling nanoparticle to ensure high encapsulation.

 

At physiological pH, LNPs are neutral, eliminating a mechanism of toxicity seen with permanently cationic molecules.

 

These same pH-sensitive lipids are responsible for responding to the acidic environment of the endosome and triggering the disruption of the endosome and release of the nucleic acid into the cell.

Nucleic Acid Lipid Nanoparticle

Both the chemistry and the process determine the outcome.

 

LNPs made with the NanoAssemblr™ platform have a unique homogeneous structure that is more effective compared to other methods of manufacture such as T-tube mixing. 



NanoAssemblr v Conventional T-tube
LNPs made with NanoAssemblr® Technology and containing siRNA against Factor VII results in more effective in vivo gene knockdown than those made with a T-junction. Lower bars indicate more effective knockdown of Factor VII measured in serum of mice treated intravenously with the indicated dose of siRNA.

Product Information

GenVoy-ILM is a pre-blended lipid mix in ethanol and is available in two formats with or without added dye for visualization.

 

• 2 mL

• 5 mL

GenVoy-ILM Vials

The Process is Part of The Outcome

NanoAssemblr® technology is necessary to produce high-quality LNPs. GenVoy-ILM is optimized for use with the NanoAssemblr® Benchtop.

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Video

July 26, 2016

Liposomes: from Prototype to the Clinic | Norbert Maurer, Transferra Nanosciences

Read More

Poster

June 11, 2018

Rapid development and seamless scale-up of genetic nanomedicines

Read More PDF

Publication - Summary

December 19, 2017

Cell Reports

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

An D, Schneller JL, Frassetto A, Liang S, Zhu X, Park JS, Theisen M, Hong SJ,Zhou J, Rajendran R, BeccaLevy B, Howell R,...

Read More

Publication - Summary

January 19, 2016

Proceedings of the National Academy of Sciences

Modular Degradable Dendrimers Enable Small RNAs to Extend Survival in an Aggressive Liver Cancer Model

Zhou K, Nguyen LH, Miller JB, Yan Y, Kos P, Xiong H, Li L, Hao J, Minnig JT, Zhu H, Siegwart DJ

Read More

Publication - Abstract

June 03, 2017

Molecular Pharmaceutics

Formulation of Non-Ionic Surfactant Vesicles (NISV) Prepared by Microfluidics for Therapeutic Delivery of siRNA into Cancer Cells

Obeid MA, Elburi A, Young LC, Mullen AB, Tate RJ, Ferro VA

Read More

Publication - Abstract

February 27, 2018

Cell Reports

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

J. Finn, A. Smith, M. Patel, L. Shaw, M. Youniss, J. Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. Shah...

Read More
Resource Center

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.